Anti-metastatic Potential of Natural Triterpenoid Cucurbitacin B Against Cholangiocarcinoma Cells by Targeting Src Protein

Owing to the crucial role of Src in cancer metastasis, interruption of Src and its signaling has been considered a promising strategy for cancer metastasis treatment. Cucurbitacin B, a dietary triterpenoid, has been shown to possess anti-proliferative and apoptosis-inducing activities in cholangiocarcinoma (CCA) cells via suppressing the activation of FAK which is a main downstream Src effector. We hypothesized that cucurbitacin B might act as a Src suppressant which conferring anti-metastasis effect against CCA cells. To investigate this, the role of Src in regulating metastasis behavior of CCA cells and the effect of cucurbitacin B on Src-mediated metastatic phenotype of these cells were determined. The results showed that activation of Src significantly enhanced the migratory and invasive abilities of CCA cells. Molecular analysis revealed that Src-facilitated metastasis behavior of CCA cells occurred by modifying expression of a wide range of metastasis-related genes in the cells. Consistent with gene expression results, activation of Src significantly induced the protein expression of 2 important metastasis-associated molecules, MMP-9 and VEGF. Cucurbitacin B markedly suppressed activation of Src and its key effector, FAK. As a consequence, the alteration of expression profiles of metastasis-associated genes induced by Src activator in CCA cells was diminished by cucurbitacin B treatment. The compound also down-regulated Src-induced expression of MMP-9 and VEGF proteins in the cells. Moreover, molecular docking analysis revealed that cucurbitacin B could interact with Src kinase domain and possibly restrain the kinase from being activated by hindering the ATP binding. In conclusion, cucurbitacin B exhibited anti-metastatic property in CCA cells via negatively influencing Src and Src-related oncogenic signaling. This compound may therefore be a potential therapeutic drug for further development as an anti-Src agent for treatment of metastatic CCA.

[1]  R. Rossi,et al.  Clinical treatment of cholangiocarcinoma: an updated comprehensive review. , 2022, Annals of hepatology.

[2]  Yen-Cheng Chen,et al.  Targeting Src-Hic-5 Signal Cascade for Preventing Migration of Cholangiocarcinoma Cell HuCCT1 , 2022, Biomedicines.

[3]  Jing Yang,et al.  Tumor metastasis: Mechanistic insights and therapeutic interventions , 2021, MedComm.

[4]  A. Fiorentino,et al.  Non-surgical treatment of hilar cholangiocarcinoma , 2021, World journal of gastrointestinal oncology.

[5]  H. Cárdenas,et al.  Hydroethanolic Extracts of the Aristotelia Chilensis (Maqui) Berry Reduces Cellular Viability and Invasiveness in the Endometrial Cancer Cell Line Ishikawa , 2021, Integrative cancer therapies.

[6]  L. Senggunprai,et al.  Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. , 2020, The American journal of Chinese medicine.

[7]  G. Barillari.  The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process , 2020, International journal of molecular sciences.

[8]  S. Uddin,et al.  Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches , 2020, Cancers.

[9]  D. Muntham,et al.  Clinical Prognostic Factors and Treatment Outcomes for the Survival of Patients with Cholangiocarcinoma in the Eastern Region of Thailand , 2019, Asian Pacific Journal of Cancer Care.

[10]  Y. Hsieh,et al.  Thymoquinone inhibits metastasis of renal cell carcinoma cell 786-O-SI3 associating with downregulation of MMP-2 and u-PA and suppression of PI3K/Src signaling , 2019, International journal of medical sciences.

[11]  S. Pereira,et al.  Molecular Pathogenesis of Cholangiocarcinoma , 2019, BMC Cancer.

[12]  Muhammad Maqsood Alam,et al.  Potential phytochemicals in the fight against skin cancer: Current landscape and future perspectives. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  L. Senggunprai,et al.  The Inhibition Kinetics and Potential Anti-Migration Activity of NQO1 Inhibitory Coumarins on Cholangiocarcinoma Cells , 2018, Integrative cancer therapies.

[14]  H. Jang,et al.  Cucurbitacin B Induces Hypoglycemic Effect in Diabetic Mice by Regulation of AMP-Activated Protein Kinase Alpha and Glucagon-Like Peptide-1 via Bitter Taste Receptor Signaling , 2018, Front. Pharmacol..

[15]  N. Akhtar,et al.  Plant derived anticancer agents: A green approach towards skin cancers. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  J. Iqbal,et al.  Potential phytocompounds for developing breast cancer therapeutics: Nature’s healing touch , 2018, European journal of pharmacology.

[17]  N. Khuntikeo,et al.  Current Perspectives on Opisthorchiasis Control and Cholangiocarcinoma Detection in Southeast Asia , 2018, Front. Med..

[18]  S. Kaul,et al.  Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms (Review). , 2017, International journal of oncology.

[19]  L. Fabris,et al.  Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. , 2017, Gene expression.

[20]  James T. Webber,et al.  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. , 2016, Cancer discovery.

[21]  Sun Young Park,et al.  Cucurbitacin B inhibits immunomodulatory function and the inflammatory response in macrophages , 2015, Immunopharmacology and immunotoxicology.

[22]  Arthur J Olson,et al.  Small-molecule library screening by docking with PyRx. , 2015, Methods in molecular biology.

[23]  S. Boxer,et al.  A conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity , 2013, Nature chemical biology.

[24]  Abdullah A Alghasham,et al.  Cucurbitacins - a promising target for cancer therapy. , 2013, International journal of health sciences.

[25]  Pei-Hsuan Chen,et al.  Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways. , 2011, The Journal of nutritional biochemistry.

[26]  R. Agarwal,et al.  Role of E-cadherin in Antimigratory and Antiinvasive Efficacy of Silibinin in Prostate Cancer Cells , 2011, Cancer Prevention Research.

[27]  E. Grande,et al.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer , 2010, OncoTargets and therapy.

[28]  Jie Zhang,et al.  SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. , 2007, The American journal of pathology.

[29]  J. Guan,et al.  Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1. , 2005, World journal of gastroenterology.

[30]  T. Boggon,et al.  Structure and regulation of Src family kinases , 2004, Oncogene.

[31]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[32]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[33]  T. Yeatman,et al.  Role of Src expression and activation in human cancer , 2000, Oncogene.

[34]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.